Precision Medicine Approaches for Neurodegeneration

Precision Medicine Approaches for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Precision Medicine Approaches for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Therapeutic Strategy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Genotype-guided, biomarker-stratified therapy</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, FTD</td>
</tr>
<tr>
<td class="label">Goal</td>
<td>Match therapies to individual patient characteristics</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Research to Early Clinical</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">[APOE](/proteins/apoe-protein) ε4 carriers</td>
<td>Anti-amyloid, anti-[tau](/proteins/tau) immunotherapy</td>
</tr>
<tr>
<td class="label">[APP](/entities/app-protein)/PSEN1/PSEN2 mutations</td>
<td>Disease-modifying therapies</td>
</tr>
<tr>
<td class="label">[TREM2](/proteins/trem2-protein) variants</td>
<td>[TREM2](/genes/trem2) agonists, [microglia](/entities/microglia) modulators</td>
</tr>
<tr>
<td class="label">Risk genes (CLU, PICALM)</td>
<td>Targeted approaches</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">LRRK2 G2019S</td>
<td>

Precision Medicine Approaches for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Precision Medicine Approaches for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Therapeutic Strategy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Genotype-guided, biomarker-stratified therapy</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, FTD</td>
</tr>
<tr>
<td class="label">Goal</td>
<td>Match therapies to individual patient characteristics</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Research to Early Clinical</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">[APOE](/proteins/apoe-protein) ε4 carriers</td>
<td>Anti-amyloid, anti-[tau](/proteins/tau) immunotherapy</td>
</tr>
<tr>
<td class="label">[APP](/entities/app-protein)/PSEN1/PSEN2 mutations</td>
<td>Disease-modifying therapies</td>
</tr>
<tr>
<td class="label">[TREM2](/proteins/trem2-protein) variants</td>
<td>[TREM2](/genes/trem2) agonists, [microglia](/entities/microglia) modulators</td>
</tr>
<tr>
<td class="label">Risk genes (CLU, PICALM)</td>
<td>Targeted approaches</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">LRRK2 G2019S</td>
<td>LRRK2 inhibitors</td>
</tr>
<tr>
<td class="label">GBA1 mutations</td>
<td>Enzyme enhancement, chaperones</td>
</tr>
<tr>
<td class="label">SNCA multiplications</td>
<td>Anti-[α-synuclein](/proteins/alpha-synuclein) therapies</td>
</tr>
<tr>
<td class="label">PARKIN, PINK1, DJ-1</td>
<td>Mitochondrial protectors</td>
</tr>
<tr>
<td class="label">LRRK2 + GBA1</td>
<td>Combination approaches</td>
</tr>
<tr>
<td class="label">Genetic Risk</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">SOD1 mutations</td>
<td>ASO therapy (tofersen)</td>
</tr>
<tr>
<td class="label">[C9orf72](/entities/c9orf72)</td>
<td>ASO therapy</td>
</tr>
<tr>
<td class="label">FUS mutations</td>
<td>ASO therapy</td>
</tr>
<tr>
<td class="label">TARDBP</td>
<td>Targeting [TDP-43](/proteins/tdp-43)</td>
</tr>
<tr>
<td class="label">ALS2</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Genetic Feature</td>
<td>Therapy Approach</td>
</tr>
<tr>
<td class="label">[HTT](/proteins/htt-protein) CAG repeat</td>
<td>ASO therapy (tominersen)</td>
</tr>
<tr>
<td class="label">CAG length</td>
<td>Treatment timing</td>
</tr>
<tr>
<td class="label">Genetic modifiers</td>
<td>Personalized approaches</td>
</tr>
<tr>
<td class="label">Biomarker Category</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">A (Amyloid)</td>
<td>CSF [Aβ42](/proteins/amyloid-beta), PET</td>
</tr>
<tr>
<td class="label">T (Tau)</td>
<td>CSF p-[tau](/proteins/tau), PET</td>
</tr>
<tr>
<td class="label">N (Neurodegeneration)</td>
<td>FDG-PET, [NfL](/proteins/nfl-protein), MRI</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Test Method</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Plasma (SimOA)</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Plasma/CSF</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Plasma</td>
</tr>
<tr>
<td class="label">MAPT genotype</td>
<td>Blood/WGS</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Test Method</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>PET (PI-2620, PM-PBB3)</td>
</tr>
<tr>
<td class="label">DAT Scan</td>
<td>SPECT</td>
</tr>
<tr>
<td class="label">CSF total tau</td>
<td>Lumbar puncture</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Variant</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>H1/H1 homozygous</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>p.R406W</td>
</tr>
<tr>
<td class="label">GBA1</td>
<td>N370S, other</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>G2019S</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>Repeat expansion</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>R47H, R62H</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Age</td>
<td>50</td>
</tr>
<tr>
<td class="label">Sex</td>
<td>Male</td>
</tr>
<tr>
<td class="label">DAT scan</td>
<td>Confirmed loss</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">Genetic panel</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">Subtype</td>
<td>Characteristics</td>
</tr>
<tr>
<td class="label">Typical AD</td>
<td>Amnestic, amyloid+/tau+</td>
</tr>
<tr>
<td class="label">Posterior cortical atrophy</td>
<td>Visual, occipital</td>
</tr>
<tr>
<td class="label">Logopenic PPA</td>
<td>Language, left temporal</td>
</tr>
<tr>
<td class="label">Dysexecutive AD</td>
<td>Frontal</td>
</tr>
<tr>
<td class="label">Rapid progression</td>
<td>Fast decline</td>
</tr>
<tr>
<td class="label">Subtype</td>
<td>Characteristics</td>
</tr>
<tr>
<td class="label">TD (Tremor-dominant)</td>
<td>Tremor, slow progression</td>
</tr>
<tr>
<td class="label">PIGD (Postural instability)</td>
<td>Falls, rapid progression</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>Early dementia</td>
</tr>
<tr>
<td class="label">Mood/anxiety</td>
<td>Depression, anxiety</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">CYP2D6</td>
<td>Bromocriptine, pergolide</td>
</tr>
<tr>
<td class="label">COMT</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">[APOE](/genes/apoe)</td>
<td>[Donepezil](/entities/donepezil), immunotherapy</td>
</tr>
<tr>
<td class="label">SCN1A</td>
<td>Carbamazepine (seizures)</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Basket trials</td>
<td>Single therapy, multiple genotypes</td>
</tr>
<tr>
<td class="label">Umbrella trials</td>
<td>Multiple therapies, single disease</td>
</tr>
<tr>
<td class="label">N-of-1 trials</td>
<td>Individual patient optimization</td>
</tr>
<tr>
<td class="label">Adaptive trials</td>
<td>Interim analysis, modification</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">ALS (SOD1)</td>
<td>Tofersen (Qalsody)</td>
</tr>
<tr>
<td class="label">SMA</td>
<td>Nusinersen (Spinraza)</td>
</tr>
<tr>
<td class="label">Prion disease</td>
<td>Prion disease</td>
</tr>
</table>

Precision Medicine Approaches For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Precision Medicine Approaches for Neurodegeneration [@schork2019]

Overview

Precision medicine aims to tailor therapeutic interventions based on individual patient characteristics, including genetic background, biomarker profiles, disease subtype, and clinical presentation. In neurodegeneration, this approach seeks to overcome the high failure rate of clinical trials by stratifying patients and matching them to targeted therapies.

Genetic Stratification

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Biomarker Stratification

Amyloid/Tau/Neurodegeneration (ATN) Framework

Practical Implementation

CBS/PSP Patient Stratification

Clinical Challenge

Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) present significant stratification challenges due to:

• Phenotypic heterogeneity: Variable motor, cognitive, and behavioral presentations
• Pathological overlap: Both feature 4R-tauopathy with overlapping features
• Mixed pathologies: Frequent co-pathology with AD (amyloid) or Lewy bodies
• Variable progression rates: Survival ranges from 3-15 years post-diagnosis

Biomarker-Guided Treatment Selection

Tier 1: Essential Biomarkers

Tier 2: Advanced Biomarkers

Genetic Subtype Mapping

Key Genes for CBS/PSP Stratification

Patient Stratification Algorithm

Treatment Selection by Subtype

For Primary 4R-Tauopathy (p-tau217 negative)

Priority interventions:

Avoid:

• Anti-amyloid therapies (lecanemab, donanemab) — not targeted
• Standard anti-PD medications alone — insufficient

For AD Co-Pathology (p-tau217 positive)

Priority interventions:

Consider:

• Donepezil/galantamine for cognitive symptoms
• Higher levodopa doses may be needed

For Rapid Progressors (NfL >60 pg/mL)

Aggressive approach:

• Anti-tau + anti-inflammatory
• Anti-tau + mitochondrial support

Case Example: 50-Year-Old Male

For the patient case (50yo male, suspected CBS/PSP, DAT scan confirmed dopamine loss):

Initial recommendations pending biomarker results:

• Priority: Enroll in anti-tau trial (E2814, BIIB080)
• Consider: OGA inhibitor, CoQ10, lifestyle

• Priority: Consider anti-amyloid if early MCI
• Combination approach required

• Optimize levodopa (up to 2000mg with entacapone)
• Start CoQ10 600mg daily
• High-intensity exercise 150+ min/week
• Implement sleep/circadian optimization

Disease Subtype Classification

Alzheimer's Disease Variants

Parkinson's Disease Variants

Pharmacogenomics

Drug Response Prediction

Emerging Applications

• Polygenic risk scores for treatment response
• Pharmacokinetic gene panels
• Adverse reaction prediction

Clinical Trial Design

Precision Medicine Trials

Example Programs

• [DIAN](/entities/dian-study): Dominantly Inherited Alzheimer's Network Trials
• Parkinson's Progression Markers Initiative (PPMI)
• ALS Genetics
• Rare Diseases

Implementation Challenges

Technical Challenges

• Comprehensive genetic testing availability
• Biomarker standardization
• Data integration
• Regulatory approval for companion diagnostics

Practical Barriers

• Cost of genetic testing
• Patient access
• Physician education
• Healthcare system integration

Ethical Considerations

• Genetic privacy
• Informed consent
• Incidental findings
• Health disparities

Current Applications

FDA-Approved Precision Therapies

In Development

• LRRK2 inhibitors for PD (DNL151, BIIB122)
• Anti-amyloid antibodies for APOE ε4 carriers
• ASOs for C9orf72 ALS/FTD
• TREM2 agonists for AD

Research Directions

• Multi-omics integration
• Digital biomarker development
• Real-world evidence generation
• International data sharing

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Genetic Testing for Neurodegeneration](/technologies/genetic-testing-neurodegeneration)
• [Biomarkers](/biomarkers)
• [Clinical Trials](/clinical-trials-index)
• [Tofersen](/therapeutics/tofersen)
• [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors)

External Links

• [NIH Precision Medicine Initiative](https://nih.gov/precision-medicine-initiative)
• [FDA Companion Diagnostics](https://fda.gov/companion-diagnostics)
• [DIAN-TU Trial](https://dian-tu.org/)
• [PPMI Study](https://ppmi-info.org/)
• [ClinicalTrials.gov - Precision Medicine](https://clinicaltrials.gov/)

Background

The study of Precision Medicine Approaches For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References